NCT05430373View on ClinicalTrials.gov

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumors, Adult
Interventions
BIOLOGICAL

GT101

Autologous tumor infiltrating lymphocyte injection

Trial Locations (5)

100039

RECRUITING

The fifth medical center of the General Hospital of the Chinese people's Liberation Army, Beijing

201321

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

400030

RECRUITING

Chongqing University Cancer Center, Chongqing

610064

RECRUITING

West China School of Medicine/West China Hospital of Sichuan University, Chengdu

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
lead

Grit Biotechnology

INDUSTRY

NCT05430373 - GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter